Patients with relapsed/refractory FLT3-mutant AML were studied in the ADMIRAL trial, which compared the use of the FLT3 inhibitor gilteritinib to treatment with salvage chemotherapy [84,85]. The gene discussed is FLT3; the disease is acute myeloid leukemia.